Return On Capital Employed Overview: Arcturus Therapeutics

During Q1, Arcturus Therapeutics's ARCT reported sales totaled $2.13 million. Despite a 85.53% in earnings, the company posted a loss of $57.67 million. In Q4, Arcturus Therapeutics brought in $2.24 million in sales but lost $31.08 million in earnings.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Arcturus Therapeutics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Arcturus Therapeutics posted an ROCE of -0.16%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Arcturus Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

For Arcturus Therapeutics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Q1 Earnings Insight

Arcturus Therapeutics reported Q1 earnings per share at $-2.15/share, which did not meet analyst predictions of $-1.25/share.